acerta-pharma.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
User-agent: * Sitemap: | ||
Meta Tags
| Title | Acerta Pharma - A Member of the AstraZeneca |
| Description | Developing novel targeted therapeutics for the treatment of Acerta Pharma is a leader in the field of covalent binding technology who is applying this technology to create novel, highly selective therapies for |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 13.226.14.122 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
acerta-pharma.com Valuation
|
US$6,073,509
Last updated: 2023-05-08 03:11:15
acerta-pharma.com has Semrush global rank of 1,742,700. acerta-pharma.com has an estimated worth of US$ 6,073,509, based on its estimated Ads revenue. acerta-pharma.com receives approximately 700,790 unique visitors each day. Its web server is located in United States, with IP address 13.226.14.122. According to SiteAdvisor, acerta-pharma.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$6,073,509 |
| Daily Ads Revenue | US$5,607 |
| Monthly Ads Revenue | US$168,190 |
| Yearly Ads Revenue | US$2,018,274 |
| Daily Unique Visitors | 46,720 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| acerta-pharma.com. | A | 299 | IP: 13.226.14.122 |
| acerta-pharma.com. | A | 299 | IP: 13.226.14.19 |
| acerta-pharma.com. | A | 299 | IP: 13.226.14.40 |
| acerta-pharma.com. | A | 299 | IP: 13.226.14.21 |
| acerta-pharma.com. | NS | 86400 | NS Record: ns-1229.awsdns-25.org. |
| acerta-pharma.com. | NS | 86400 | NS Record: ns-154.awsdns-19.com. |
| acerta-pharma.com. | NS | 86400 | NS Record: ns-1775.awsdns-29.co.uk. |
| acerta-pharma.com. | NS | 86400 | NS Record: ns-979.awsdns-58.net. |
| acerta-pharma.com. | MX | 300 | MX Record: 10 de-smtp-inbound-1.mimecast.com. |
| acerta-pharma.com. | MX | 300 | MX Record: 10 de-smtp-inbound-2.mimecast.com. |
| acerta-pharma.com. | TXT | 3600 | TXT Record: docusign=659822aa-19c9-4f44-bfeb-c71349bba3f3 |
| acerta-pharma.com. | TXT | 3600 | TXT Record: docusign=a853dfea-fafd-435f-9623-123582c15303 |
| acerta-pharma.com. | TXT | 3600 | TXT Record: v=spf1 include:spf.mandrillapp.com ip4:74.116.124.0/22 ip4:199.168.64.0/22 ip4:210.129.217.47/32 include:mailgun.org include:de._netblocks.mimecast.com ~all |
| acerta-pharma.com. | TXT | 3600 | TXT Record: workplace-domain-verification=fpszGCBQJw36LAEShxR85Rh9nGnH26 |
| acerta-pharma.com. | TXT | 3600 | TXT Record: A0S0T21378 |
| acerta-pharma.com. | TXT | 3600 | TXT Record: CcGeFfvW1R35XD/CuF8ZdxSBSMoi8HhAfwY2vk0buB+CtcdVTcFQTggWjxE66R1IiJzU56pe22j5k4QoKcjWfg== |
| acerta-pharma.com. | TXT | 3600 | TXT Record: MS=ms43635581 |
| acerta-pharma.com. | TXT | 3600 | TXT Record: MS=ms74803637 |
HtmlToTextCheckTime:2023-05-08 03:11:15
| Toggle navigation Medicines Medicines More Hide About Us Leadership Board of Directors Founders Our Science Drug Discovery Innovative Clinical Studies Resistance Biology Translational Medicine BTK Overview Acalabrutinib Overview Our Pipeline Partnering Join Our Team News Contact About Us Leadership Board of Directors Founders Our Science Drug Discovery Innovative Clinical Studies Resistance Biology Translational Medicine BTK Overview Acalabrutinib Overview Our Pipeline Partnering Join Our Team News Contact Developing novel targeted therapeutics for the treatment of cancer. Learn More Acerta Pharma is a leader in the field of covalent binding technology and is applying this technology to create novel, highly selective therapies for cancer. In February 2016, AstraZeneca acquired a majority share of Acerta Pharma via a USD $4 billion investment and is a committed partner to the development of these innovative drugs. Featured News CALQUENCE granted US Breakthrough Therapy Designation for |
HTTP Headers
HTTP/1.1 403 Forbidden Server: CloudFront Date: Fri, 29 Oct 2021 05:52:56 GMT Content-Type: text/html Content-Length: 919 Connection: keep-alive X-Cache: Error from cloudfront Via: 1.1 bc779a771e58cc6656070a41635de578.cloudfront.net (CloudFront) X-Amz-Cf-Pop: ORD51-C2 X-Amz-Cf-Id: kvRKG36abrpUZ2PM-XwZEEValWASFeYqu6WAt7KEWmTgg-A1PHNL3Q== |
acerta-pharma.com Whois Information
Domain Name: ACERTA-PHARMA.COM Registry Domain ID: 1751669822_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.corporatedomains.com Registrar URL: http://cscdbs.com Updated Date: 2020-12-18T18:34:07Z Creation Date: 2012-10-12T15:42:31Z Registry Expiry Date: 2023-10-12T15:42:31Z Registrar: CSC Corporate Domains, Inc. Registrar IANA ID: 299 Registrar Abuse Contact Email: domainabuse@cscglobal.com Registrar Abuse Contact Phone: 8887802723 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: NS-1229.AWSDNS-25.ORG Name Server: NS-154.AWSDNS-19.COM Name Server: NS-1775.AWSDNS-29.CO.UK Name Server: NS-979.AWSDNS-58.NET DNSSEC: unsigned >>> Last update of whois database: 2021-09-16T20:18:22Z <<< |